Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Drug

D0055 | Fenofibrate

Molecular Formula C20H21ClO4
Molecular Weight 360.8
Structure
State solid
Clearance * 1.2 L/h [Eldery]
Volume of distribution In healthy adults, the volume of distribution is 30 L. The volume of distribution is 95 L in individuals with moderate renal impairment and creatinine clearance of 50 to 90 mL/min [FDA Label].
Route of elimination Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.
Protein binding Serum protein binding is reported to be around 99% [FDA Label].
Half life 20 hours
Absorption Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
Trade names Tricor
Description a fibric acid derivative; treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia

C

C10BA04 Simvastatin and fenofibrate


[C10BA] HMG CoA reductase inhibitors in combination with other lipid modifying agents


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10BA03 Pravastatin and fenofibrate


[C10BA] HMG CoA reductase inhibitors in combination with other lipid modifying agents


[C10B] LIPID MODIFYING AGENTS, COMBINATIONS


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

C10AB05 Fenofibrate


[C10AB] Fibrates


[C10A] LIPID MODIFYING AGENTS, PLAIN


[C10] LIPID MODIFYING AGENTS


[C] Cardiovascular system

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 281 companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


Reported as not meeting GHS hazard criteria by 2 of 281 companies. For more detailed information, please visit ECHA C&L website


Of the 12 notification(s) provided by 279 of 281 companies with hazard statement code(s):


H373 (92.47%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure]


H413 (91.76%): May cause long lasting harmful effects to aquatic life [Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P260, P273, P314, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

  • Aortic aneurysm

  • Blood triglycerides increased

  • Cardiac disorder

  • Carotid artery disease

  • Combined hyperlipidaemia

  • Coronary artery disease

  • Diabetic retinopathy

  • High density lipoprotein decreased

  • Hypercholesterolaemia

  • Hyperchylomicronaemia

  • Hypothyroidism

  • Low density lipoprotein increased

  • Obesity

  • Pancreatitis

  • Peripheral arterial occlusive disease

  • Peripheral vascular disorder

  • Renal failure

  • Renal impairment

  • Type 2 diabetes mellitus

  • Type I hyperlipidaemia

  • Type IV hyperlipidaemia

  • Weight decreased

  • Disturbance in sexual arousal (0.00533)

  • Libido decreased (0.00533)

  • Abdominal pain

  • Alanine aminotransferase increased

  • Arthralgia

  • Aspartate aminotransferase increased

  • Asthenia

  • Back pain

  • Blood creatine phosphokinase increased

  • Bronchitis

  • Chest pain

  • Conjunctivitis

  • Constipation

  • Dermatitis

  • Diarrhoea

  • Discomfort

  • Dizziness

  • Dyspepsia

  • Fatigue

  • Feeling abnormal

  • Flatulence

  • Gastrointestinal pain

  • Headache

  • Ill-defined disorder

  • Influenza

  • Injury

  • Insomnia

  • Liver function test abnormal

  • Malaise

  • Malnutrition

  • Muscle spasms

  • Musculoskeletal discomfort

  • Myalgia

  • Nasopharyngitis

  • Nausea

  • Pain

  • Pain in extremity

  • Pharyngitis

  • Pruritus

  • Rash

  • Rhinitis

  • Sinusitis

  • Upper respiratory tract infection

  • Urticaria

    • 1-methylethyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methyl-ethyl ester
    2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid isopropyl ester 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid Isopropyl Ester
    2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid,1-methylethylester 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoicacidisopropylester 2-[4-[(4-chlorophenyl)-oxomethyl]phenoxy]-2-methylpropanoic acid propan-2-yl ester
    28073-EP2272825A2 28073-EP2272841A1 28073-EP2277565A2
    28073-EP2277566A2 28073-EP2277567A1 28073-EP2277568A2
    28073-EP2277569A2 28073-EP2277570A2 28073-EP2287163A1
    28073-EP2287165A2 28073-EP2287166A2 28073-EP2292280A1
    28073-EP2292620A2 28073-EP2295409A1 28073-EP2298742A1
    28073-EP2298776A1 28073-EP2301923A1 28073-EP2301936A1
    28073-EP2305678A1 28073-EP2314588A1 49562-28-9
    562F289 A827746 AB00052196
    AB00052196-15 AB00052196-16 AB00052196_17
    AB00052196_18 AB0012237 AB03716
    AB2000298 AC-4227 AK-88651
    AKOS005107777 ALBB-028958 ANW-41658
    API0003184 API0025994 API0026002
    API0026009 AX8021009 Ankebin
    Antara Antara (TN) Antara (micronized)
    BCP21243 BDBM50085042 BG0483
    BIDD:GT0574 BPBio1_000166 BRD-K50388907-001-05-6
    BRD-K50388907-001-18-9 BRD-K50388907-001-20-5 BRN 2062462
    BSPBio_000150 BSPBio_003162 C-20905
    C07586 C20H21ClO4 CAS-49562-28-9
    CC-28385 CCG-38996 CCRIS 7282
    CHEBI:5001 CHEMBL672 CIP-Fenofibrate
    CPD000058299 CS-0892 CTK8B3039
    Certified Reference Material D00565 DB-051642
    DB01039 DSSTox_CID_9874 DSSTox_GSID_29874
    DSSTox_RID_78828 DTXSID2029874 DivK1c_000557
    EBD45918 EC 256-376-3 EINECS 256-376-3
    EU-0100486 Elasterate Elasterin
    F 6020 F0674 FENOFIBRATE (MICRONIZED)
    FENOFIBRATE (MICRONIZED) (fenofibrate FNF FT-0626400
    FT-0654669 Fenobrate Fenofibrate (JAN/INN)
    Fenofibrate (Tricor, Trilipix) Fenofibrate IDD-P Fenofibrate [INN:BAN]
    Fenofibrate [USAN:USP:INN:BAN] Fenofibrate(Tricor) Fenofibrate, 98%
    Fenofibrate, >=99%, powder Fenofibrate, European Pharmacopoeia (EP) Reference Standard Fenofibrate, Pharmaceutical Secondary Standard
    Fenofibrate, United States Pharmacopeia (USP) Reference Standard Fenofibrate, analytical reference material Fenofibrate,(S)
    Fenofibrato Fenofibrato [INN-Spanish] Fenofibratum
    Fenofibratum [INN-Latin] Fenogal Fenoglide
    Fenomax Fenotard Finofibrate
    Fulcro GP4850 GRS-027
    GTPL7186 HMS1568H12 HMS1921B17
    HMS2090G20 HMS2092B05 HMS2095H12
    HMS2231B14 HMS3259K03 HMS3261B13
    HMS3369M13 HMS3649D20 HMS3655K12
    HMS3712H12 HMS501L19 HSDB 7736
    HY-17356 IDI1_000557 Isopropyl (4''-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate
    Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoate Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate
    Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate Isopropyl 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionate Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate
    J10318 K-9221 KBio1_000557
    KBio2_001730 KBio2_004298 KBio2_006866
    KBio3_002382 KBioGR_000706 KBioSS_001730
    KS-00000655 LCP-Feno LCP-FenoChol
    LF 178 LF-178 LP00486
    LS-121256 Lipanthyl Lipantil
    Lipantil (TN) Lipidex Lipidil
    Lipifen Lipirex Lipoclar
    Lipofen Lipofen (TN) Lipofene
    Liposit Lipsin Lofibra
    Lopac-F-6020 Lopac0_000486 Luxacor
    MCULE-9460650238 MFCD00133314 MLS000028515
    MLS001148191 MLS002548878 MS-2223
    NC00452 NCGC00015437-01 NCGC00015437-02
    NCGC00015437-03 NCGC00015437-04 NCGC00015437-05
    NCGC00015437-06 NCGC00015437-07 NCGC00015437-08
    NCGC00015437-09 NCGC00015437-10 NCGC00015437-11
    NCGC00015437-12 NCGC00015437-13 NCGC00015437-14
    NCGC00015437-16 NCGC00015437-17 NCGC00021475-03
    NCGC00021475-04 NCGC00021475-05 NCGC00021475-06
    NCGC00021475-07 NCGC00021475-08 NCGC00253945-01
    NCGC00261171-01 NINDS_000557 NSC 281319
    NSC-281319 NSC-757822 NSC281319
    NSC757822 Nolipax Opera_ID_328
    Pharmakon1600-01501010 Pharmavit Phenofibrate
    Prestwick0_000275 Prestwick1_000275 Prestwick2_000275
    Prestwick3_000275 Prestwick_217 Procetofen
    Procetofene Procetoken Proctofene
    Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethylester
    Protolipan PubChem17489 Q-201111
    Q419724 SAM002264613 SBB037926
    SBI-0050470.P003 SCHEMBL4670 SMR000058299
    SPBio_001380 SPBio_002369 SPECTRUM1501010
    SR-01000000091 SR-01000000091-16 SR-01000000091-2
    SR-01000000091-5 SR-01000000091-6 SR-01000000091-8
    ST085313 SW196525-4 Secalip
    Sedufen Spectrum2_001390 Spectrum3_001431
    Spectrum4_000413 Spectrum5_001479 Spectrum_001250
    Supralip TC-130403 TRICOR (MICRONIZED)
    Tox21_110147 Tox21_110147_1 Tox21_300151
    Tox21_500486 Tricor Tricor (TN)
    Triglide Triglide (TN) U202363UOS
    UNII-U202363UOS YMTINGFKWWXKFG-UHFFFAOYSA-N Z2768724415
    ZINC584092 ZX-AN079771 fenofibrate
    fenofibrate; isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoate isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate
    methylethyl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate propan-2-yl 2-[4-(4-chlorophenyl)carbonylphenoxy]-2-methyl-propanoate
    propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate s1794

    DrugBank Name Fenofibrate
    DrugBank DB01039
    CAS Number 1092484-56-4, 49562-28-9, 675576-98-4
    PubChem Compound 3339
    KEGG Compound ID C07586
    KEGG Drug D00565
    PubChem.Substance 46507371
    ChEBI 5001
    PharmGKB PA449594
    ChemSpider 3222
    BindingDB 50085042.0
    TTD DAP000270
    Wikipedia Fenofibrate
    DPD 1381

    1. Brunmair et al. (2004)
    2. Zhou et al. (1999)